MedTrace Logo

Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination

NCT05450770 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-07-30

No results posted yet for this study

Summary

ANRS 0146s NovaaTen study aims to determine the vaccine responses in the participants of the ANRS EP46 Novaa trial 10 years after a primary anti-yellow fever vaccination

Conditions

  • HIV Infections
  • Yellow Fever

Interventions

BIOLOGICAL

Yellow fever vaccination (STAMARIL)

Yellow fever vaccination (STAMARIL) for HIV positive and negative subjects

Sponsors & Collaborators

  • Saint-Louis Hospital, Paris, France

    collaborator OTHER

  • Bichat Hospital

    collaborator OTHER

  • Hôpital Cochin

    collaborator OTHER

  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Principal Investigators

  • Nathalie COLIN de VERDIERE · Maladies Infectieuses St Louis Paris

  • Odile LAUNAY · CIC Cochin Paris

  • Jade GHOSN · Hôpital Bichat Paris

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2024-11-01
Completion
2024-11-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05450770 on ClinicalTrials.gov